Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 1 · 33.3%Very low 0 · 0%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%

Low molecular weight heparin vs no prophylaxis

All‐cause mortality ( · adults undergoing KA

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1978 participants
GRADE not reported

Low molecular weight heparin vs vitamin K antagonist (VKA)

All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 0.94 [0.56, 1.59]
3 studies · 561 participants
Low

Low molecular weight heparin vs no LMWH

All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with no LMWH (low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 0.82 [0.53, 1.26]
5 studies · 1236 participants
Low